Congratulations! Journal of Yeugnam Medical Science (JYMS) was finally accepted for indexing in Scopus. On the evening of March 11, 2023, I received a call from the managing editor of JYMS with this great news. I checked through the e-mail and verified that the Scopus Content Selection and Advisory Board (CSAB) had reviewed the application and approved JYMS for coverage. The news was too good to believe.
Now, I am delighted to share this great news with the readers, authors, and reviewers of JYMS. This achievement would not have been possible without their contributions and help. I also thank the past and present editorial board members for their dedication to JYMS.
Since the inaugural issue of JYMS in 1984, there have been milestones that greatly contributed to the acceptance of JYMS to Scopus. The chronological details of JYMS until its indexation in Scopus are presented below to help the editors of other journals understand the process (Table 1).
Table 1.
The history of the Journal of Yeungnam Medical Science development
| Date | Key milestones |
|---|---|
| Dec 1984 | The inaugural issue was published in Korean with 15 articles, and its name was Yŏngnam Ŭidae haksulji in Korean |
| Jul 1994 | International standard serial number was assigned (pISSN 1225-7737) |
| Jun 1996 | The journal joined as a member of the Korean Association of Medical Journal Editors (KAMJE) |
| Dec 2004 | The journal was indexed in KoreaMed |
| Mar 2012 | The journal was indexed in KoreaScience |
| Jun 2012 | The journal’s English name was added as Yeungnam University Journal of Medicine (pISSN 1225-7737, eISSN 2234-8042) |
| Feb 2013 | The journal was indexed in KoreaMed Synapse |
| Jan 2014 | The journal became a member of the Korean Council of Science Editors (KCSE) |
| Jun 2015 | The journal began publishing articles online only |
| The journal name remained the same (Yeungnam University Journal of Medicine) and a new ISSN was issued (eISSN 2384-0293) | |
| Dec 2016 | The journal was indexed as a candidate journal in Korea Citation Index (KCI) |
| Jun 2018 | The journal adopted an English-only policy and online submission and review systems were introduced |
| Oct 2018 | The journal was indexed as an accredited journal in KCI |
| Jun 2019 | The journal was indexed in the Directory of Open Access Journals (DOAJ) |
| Oct 2019 | The journal was indexed in PubMed Central (PMC) and became searchable through PubMed |
| Jan 2020 | International-level manuscript editing was implemented through professional manuscript editing by InfoLumi (Seoul, Korea) |
| Oct 2020 | The journal was indexed in Chemical Abstracts Service (CAS) |
| Jan 2022 | The journal’s name was changed to Journal of Yeungnam Medical Science (eISSN 2799-8010) |
| The journal expanded the types of articles published: imagery, image vignette, and resident fellow section were launched | |
| Dec 2022 | The journal was indexed in ScienceCentral |
| Mar 2023 | The journal was accepted to Scopusa) |
The reviewer’s comment was as follows: “This institutional English language journal from South Korea is publishing 20–30 items per annum from all health disciplines, with a substantial increase in citation activity (>600) since last reviewed. The editors have responded constructively to the previous Scopus evaluation in 2019, and on balance, there are no obvious contraindications to accession to Scopus at this point.”
JYMS is currently awaiting evaluation for Emerging Sources Citation Index (ESCI) listing by Clarivate Analytics. If JYMS is accepted for ESCI, Journal Citation Reports (JCR) impact factor (IF) is very important for JYMS to be listed in Science Citation Index Expanded (SCIE). To increase the JCR IF, JYMS will try to publish high-quality articles that can be cited in SCIE-listed journals. JYMS will also recruit eminent editors from various countries to improve the quality of the journal. Our editorial team will do its best to make JYMS an internationally renowned journal.
Footnotes
Conflicts of interest
So-Young Park has been the editor-in-chief of Journal of Yeungnam Medical Science since 2021. Otherwise, no potential conflict of interest relevant to this article was reported.